← All trials
NCT05330884
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 15, 2022
- Primary completion
- Jun 30, 2025
- Completion date
- Dec 31, 2025
- First posted
- Apr 15, 2022
- Last posted
- Jul 7, 2022
- Enrollment
- 9200
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Institute for Research in Tuberculosis, Chennai, IndiaLead sponsor
- All India Institute of Medical SciencesCollaborator
- All India Institute of Medical SciencesCollaborator
- All India Institute of Medical SciencesCollaborator
- Institute of Child Health, ChennaiCollaborator
- Rajiv Gandhi University of Health SciencesCollaborator
- Grant Medical CollegeCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.